Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Head and Neck Cancers
•
Radiation Oncology
•
Bullous/Blistering Skin Disorders
•
Porphyria
Is it safe to offer head and neck radiotherapy to a patient with a diagnosis of porphyria such as erythropoietic protoporphyria or porphyria cutanea tarda?
Answer from: Radiation Oncologist at Academic Institution
Gunn et al., PMID 19536857.
Sign In
or
Register
to read more
11722
Related Questions
What dose and treatment area of radiation should be given when p16+/HPV ISH negative SCC is found in the scar of a level V lymph node excisional biopsy with all other workup negative?
How would you approach a patient treated for a stage I glottic cancer 2 years prior with a biopsy proven recurrence who is declining surgery and any systemic therapy?
For unresectable-appearing BRAF V600E papillary thyroid cancer involving the trachea and carotid artery, is neoadjuvant targeted therapy a viable path to surgery, or is definitive radiation the better option?
How do you counsel patients regarding alcohol consumption following treatment of head and neck cancer?
What is the role of radiation therapy for Kimura's disease of the parotid and neck?
For a patient with a salivary gland tumor with evidence of local recurrence would you recommend 6 weekly fractions if giving RT alone?
For a patient s/p TORS with indications for adjuvant radiation, how does your management change with persistently elevated ctHPVDNA?
Would you recommend adjuvant radiation for a patient with head/neck merkel cell carcinoma following a pathologic complete response to neoadjuvant immunotherapy?
What is your recommendation for patients who are on weight loss medications like GLP-1-based therapies while receiving chemoradiation for head and neck cancer?
How would the updated results of ECOG 3311 influence your adjuvant RT recommendations for HPV+ OPSCC?